ClinicalTrials.gg
Active, not recruitingNCT04639219DPT01Updated Mar 23, 2026Results posted

A Study of T-DXd for the Treatment of Solid Tumors Harboring HER2 Activating Mutations

A Phase 2 interventional study of Trastuzumab deruxtecan in Advanced Solid Tumors With HER2 Mutation,eg:Colorectal,Urothelial,Gastric, Hepatobiliary,Endometrial,Melanoma,Ovarian,Cervical,Salivary Gland,Pancreatic,Breast, sponsored by AstraZeneca. Active, not recruiting at 30 sites in 9 countries. Open to participants aged 18 Years to 120 Years. Per ClinicalTrials.gov, last updated 2026-03-23.

Sponsored by AstraZeneca · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
102
Allocation
Not applicable
Ages
18 Years to 120 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 20 studies testing trastuzumab deruxtecan in Neoplasm Metastasis — 10 open to participants now, 13 under way, 2 of them phase 3. trastuzumab deruxtecan · Neoplasm Metastasis.

Enrollment
7th of 20
102 · median 69
Started
2020
with 2 others
Phase 2
11 of 20
6 open now
Primary completion
2023-01
later than 0 of 12 live
Registered
10th of 20
by date
Lead sponsor
2 of 20
AstraZeneca

Among the 20 studies testing trastuzumab deruxtecan in Neoplasm Metastasis, this one is the 7th largest by enrollment, is one of 3 that started in 2020, is one of 11 in phase 2, reaches primary completion later than 0 of the 12 other live ones, and was the 10th registered.

Neoplasm Metastasis

4,046 studies on the registry are indexed under Neoplasm Metastasis; 889 are open to participants now.

Browse Neoplasm Metastasis studies →

Open to participants now

10 of the 20 studies testing trastuzumab deruxtecan in Neoplasm Metastasis are open now, in 12 countries. Recruiting first, the newest first:

5 more — sign in →

By country, each count listing its studies:

All 10 open studies →

About trastuzumab deruxtecan

trastuzumab deruxtecan: first FDA approval 2019 (ENHERTU), first EMA approval 2021. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 690 Neoplasm Metastasis studies recruiting now, 537 (78%) set no upper age limit and 97 (14%) stop at 75 or younger; 48 take children under 18; 18 take healthy volunteers.

This study: 18 Years to 120 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 20 studies testing trastuzumab deruxtecan in Neoplasm Metastasis, or all of them as a file.
02

Study summary

This is an open-label, multi-center, single arm, Phase II study to evaluate the efficacy and safety of T-DXd for the treatment of unresectable and/or metastatic solid tumors harboring specific HER2 activating mutations regardless of tumor histology. The target population are patients who have progressed following prior treatment or who have no satisfactory alternative treatment options, including approved second line therapies in the specific tumor type. Pre-specified HER2 mutations will be locally assessed using NGS tests or alternative methods. Prior HER2 targeting therapy is permitted.

03

Conditions studied

  • Advanced Solid Tumors With HER2 Mutation,eg:Colorectal,Urothelial,Gastric, Hepatobiliary,Endometrial,Melanoma,Ovarian,Cervical,Salivary Gland,Pancreatic,Breast

Browse trials for

Keywords

  • HER2
  • T-DXd
  • DS-8201a
  • Trastuzumab Deruxtecan
  • Metastatic
  • Solid Tumors
  • Histology Agnostic
04

Who can participate

Ages eligible
18 Years to 120 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Adults ≥18 years old. Other age restrictions may apply as per local regulations.
  • Unresectable and/or solid tumors with pre-specified mutations (S310F, S310Y, G660D, R678Q, D769Y, D769H, V777L, Y772_A775dup / A775_G776insYVMA, L755S, G778_P780dup / P780_Y781insGSP, T862A, and V842I locally determined by NGS or a validated nucleic acid-based methodology (eg, qPCR, digital PCR) on tumor tissue, who have progressed following prior treatment or who have no satisfactory alternative treatment options.
  • Prior HER2 targeted therapy is permitted.
  • All patients must provide an FFPE tumor sample for retrospective central HER2 testing.
  • ≥50%
  • 0-1
  • All patients have measurable target disease assessed by the Investigator based on v1.1

Exclusion criteria

Exclusion Criteria:

  • overexpressing (IHC3+ or IHC2+/ISH+) breast, gastric or gastroesophageal junction adenocarcinoma.
  • HER2 mutant NSCLC.
  • Medical history of myocardial infarction within 6 months before randomization/enrolment, symptomatic CHF, unstable angina pectoris, cardiac arrhythmias, or a recent (\< 6 months) cardiovascular event including stroke.
  • History of non-infectious pneumonitis/ILD, current ILD, or where suspected ILD cannot be ruled out by imaging at screening
  • interval by Fridericia's formula (QTcF) prolongation to > 470 msec (females) or > 450 msec (males) based on average of the screening triplicate 12-lead .
  • Lung-specific intercurrent clinically significant severe illnesses.
  • History of active primary immunodeficiency, known , active or infection
  • Uncontrolled infection requiring intravenous (IV) antibiotics, antivirals, or antifungals
  • Pleural effusion, ascites or pericardial effusion that requires drainage, peritoneal shunt, or Cell-free and Concentrated Ascites Reinfusion Therapy (CART).
  • Has spinal cord compression or clinically active central nervous system .
Terms in these criteria, in plain language(11)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

HER2

HER2 is a protein, made from the ERBB2 gene, that drives the growth of some cancers. A study may look for a level of the protein, extra copies of the gene, or a particular change in it.

In breast cancer, protein tests are read as HER2-positive, HER2-low or HER2-negative; other cancers use their own rules. Check which test result the study requires.

LVEF (left ventricular ejection fraction)

The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

RECIST

The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.

“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
102 participants (actual)

Study arms

  • Experimental
    T-DXd

    T-DXd monotherapy

    Drug: Trastuzumab deruxtecan

Interventions

  • Trastuzumab deruxtecan (T-DXd) by intravenous infusion

    Also known as: DS-8201a (T-DXd)

06

What researchers measure

Primary outcomes

  1. Confirmed Overall Response Rate (ORR) as Per RECIST v1.1 Using Independent Central Review (ICR)

    Confirmed ORR was defined as the percentage of participants who had a confirmed complete response (CR) or partial response (PR), as determined by ICR per RECIST v1.1. A CR was defined as disappearance of all target lesions (TLs) and PR was defined as at least a 30% decrease in the sum of the diameters (dms) of TL, taking as reference the baseline sum of diameters as long as criteria for PD were not met. An ICR of all radiological imaging data was carried out using RECIST v1.1. All images were collected centrally. The imaging scans were reviewed by 2 independent radiologists and were adjudicated, if required.

    Time frame: Tumor scans performed at screening,then every 6 weeks (q6w) +/- 1 week relative to date of first treatment administration until RECIST v1.1 objective PD, withdrawal of consent, or death by any cause, up to DCO date of 25 Jan 2023 (approximately 24 months)

Secondary outcomes

  1. Duration of Response (DoR) as Per RECIST v1.1 Using ICR and Investigator Assessment

    DoR was defined as the time from the date of first documented response until date of documented progression or death in the absence of disease progression (date of progression-free survival \[PFS\] event or censoring - date of first response + 1). The DoR was calculated using Kaplan-Meier technique.

    Time frame: Tumor scans performed at screening, then q6w +/- 1 week relative to the date of first treatment administration until RECIST v1.1 objective PD, withdrawal of consent, or death by any cause, up to DCO date of 25 Jan 2023 (approximately 24 months)

  2. Disease Control Rate (DCR) as Per RECIST v1.1 Using ICR and Investigator Assessment

    DCR at 6 weeks was defined as the percentage of participants who had the best objective response (BoR) of confirmed CR or PR, or who had stable disease (SD) (without subsequent cancer therapy), for at least 5 weeks after first dose of study treatment. DCR at 12 weeks was defined as the percentage of patients who had the BoR of confirmed CR or PR, or who had SD (without subsequent cancer therapy), for at least 11 weeks after first dose of study treatment. CR was defined as disappearance of all TL and PR was defined as at least a 30% decrease in sum of the dms of TL, taking as reference the baseline sum of dms as long as criteria for PD were not met. SD was defined as neither sufficient shrinkage to qualify for PR nor sufficient increase to qualify for PD (\>=20% increase in sum of dms of TLs and an absolute increase of \>=5 millimeters, taking as reference smallest sum of dms since treatment started including baseline sum of dms). CI was calculated using Clopper-Pearson method.

    Time frame: Tumor scans performed at screening, then q6w +/- 1 week relative to the date of first treatment administration until RECIST v1.1 objective PD, withdrawal of consent, or death by any cause, up to DCO date of 25 Jan 2023 (approximately 24 months)

  3. PFS as Per RECIST v1.1 Using ICR and Investigator Assessment

    PFS was defined as the time from first dose of study treatment until the date of objective disease progression or death (by any cause in the absence of progression) regardless of whether the participant withdrew from assigned therapy or received another anti-cancer therapy prior to progression (i.e. date of PFS event or censoring - date of first dose + 1). PFS was calculated using the Kaplan-Meier technique. CI for median PFS derived based on the Brookmeyer-Crowley method.

    Time frame: Tumor scans performed at screening, then q6w +/- 1 week relative to the date of first treatment administration until RECIST v1.1 objective PD or death by any cause, up to DCO date of 25 Jan 2023 (approximately 24 months)

  4. Percentage of Participants Alive and Progression-Free at 6 and 12 Months as Per RECIST v1.1 Using ICR and Investigator Assessment

    Percentage of participants alive and progression-free at 6 and 12 months are reported. It was calculated using the Kaplan-Meier technique. CI for median PFS derived based on the Brookmeyer-Crowley method.

    Time frame: At Months 6 and 12

  5. Confirmed ORR as Per RECIST v1.1 Using Investigator Assessment

    Confirmed ORR was defined as the percentage of participants who had a confirmed CR or PR as determined by investigator per RECIST v1.1. A CR was defined as disappearance of all TLs and PR was defined as \>=30% decrease in the sum of the dms of TL, taking as reference the baseline sum of dms as long as criteria for PD were not met.

    Time frame: Tumor scans performed at screening, then q6w +/- 1 week relative to the date of first treatment administration until RECIST v1.1 objective PD, withdrawal of consent, or death by any cause, up to DCO date of 25 Jan 2023 (approximately 24 months)

  6. Overall Survival (OS)

    OS was defined as the time from the date of first dose of study treatment administration until death due to any cause regardless of whether the patient withdrew from therapy or received another anti-cancer therapy (i.e. date of death or censoring - date of first dose + 1). OS was calculated using the Kaplan-Meier technique. CI for median OS derived based on the Brookmeyer-Crowley method.

    Time frame: From the date of first treatment administration up to death, approximately 24 months

  7. Percentage of Participants Alive at 6 and 12 Months

    Percentage of participants alive at 6 and 12 months are reported. It was calculated using the Kaplan-Meier technique. CI for median PFS derived based on the Brookmeyer-Crowley method.

    Time frame: At Months 6 and 12

  8. Serum Concentrations of T-DXd and Total Anti-HER2 Antibody

    Serum samples were collected at specified timepoints to determine serum concentrations of T-DXd and total anti-HER2 antibody.

    Time frame: Pre-infusion and 15 minutes post-infusion in Cycles 1, 2 and 4 and 5 hours post-infusion in Cycle 1 (each cycle 21 days)

  9. Serum Concentrations of Deruxtecan (MAAA-1181a)

    Serum samples were collected at specified timepoints to determine serum concentrations of MAAA-1181a.

    Time frame: Pre-infusion and 15 minutes post-infusion in Cycles 1, 2 and 4 and 5 hours post-infusion in Cycle 1 (each cycle 21 days)

  10. Percentage of Participants With Anti-Drug Antibodies (ADA) to T-DXd

    Blood samples were collected to evaluate the presence of ADAs for T-DXd using validated assays. ADA prevalence was defined as the percentage of participants with positive ADA result at any time, baseline or post-baseline. ADA incidence was defined as the percentage of participants who were evaluable for ADA and were treatment-emergent ADA-positive. Treatment-emergent ADA was defined as either treatment-induced (baseline ADA negative, post-baseline ADA positive) or treatment-boosted ADA. Treatment-boosted ADA was defined as baseline positive ADA titer that was boosted to \>=2 fold during the study period. Persistently positive was defined as \>=2 post-baseline ADA positive measurements with at least 16 weeks (112 days) between the first and last positive measurements, or an ADA positive result at the last available assessment. Transiently positive was defined as having \>=1 post baseline ADA positive measurement and not fulfilling the conditions for persistently positive.

    Time frame: Up to approximately 24 months

07

Results

Posted Feb 15, 2024

Participant flow

This Phase II multicenter, open-label study was conducted in participants with unresectable and/or metastatic solid tumors harboring human epidermal growth factor receptor 2 (HER2) activating mutations regardless of tumor histology at 29 investigational sites in 9 countries. First participant was enrolled on 30 Dec 2020, last participant was enrolled on 24 May 2022 and data cut-off (DCO) date was 25 Jan 2023.

Participant flow — Overall Study
MilestoneTrastuzumab Deruxtecan (T-DXd)
Started102
Completed33
Not completed69
Withdrew: Withdrawal by subject8
Withdrew: Lost to follow-up6
Withdrew: Death55

Outcome measures

PrimaryConfirmed Overall Response Rate (ORR) as Per RECIST v1.1 Using Independent Central Review (ICR)

Confirmed ORR was defined as the percentage of participants who had a confirmed complete response (CR) or partial response (PR), as determined by ICR per RECIST v1.1. A CR was defined as disappearance of all target lesions (TLs) and PR was defined as at least a 30% decrease in the sum of the diameters (dms) of TL, taking as reference the baseline sum of diameters as long as criteria for PD were not met. An ICR of all radiological imaging data was carried out using RECIST v1.1. All images were collected centrally. The imaging scans were reviewed by 2 independent radiologists and were adjudicated, if required.

Time frame:
Tumor scans performed at screening,then every 6 weeks (q6w) +/- 1 week relative to date of first treatment administration until RECIST v1.1 objective PD, withdrawal of consent, or death by any cause, up to DCO date of 25 Jan 2023 (approximately 24 months)
Reported as:
Number · percentage of participants
Confirmed Overall Response Rate (ORR) as Per RECIST v1.1 Using Independent Central Review (ICR)
percentage of participantsT-DXd
Confirmed Overall Response Rate (ORR) as Per RECIST v1.1 Using Independent Central Review (ICR)29.4 (20.8 to 39.3)
SecondaryDuration of Response (DoR) as Per RECIST v1.1 Using ICR and Investigator Assessment

DoR was defined as the time from the date of first documented response until date of documented progression or death in the absence of disease progression (date of progression-free survival \[PFS\] event or censoring - date of first response + 1). The DoR was calculated using Kaplan-Meier technique.

Time frame:
Tumor scans performed at screening, then q6w +/- 1 week relative to the date of first treatment administration until RECIST v1.1 objective PD, withdrawal of consent, or death by any cause, up to DCO date of 25 Jan 2023 (approximately 24 months)
Reported as:
Median · months
Duration of Response (DoR) as Per RECIST v1.1 Using ICR and Investigator Assessment
monthsT-DXd
DoR by ICRNA (6.8 to NA)
DoR by Investigator assessment11.0 (6.9 to 18.1)
SecondaryDisease Control Rate (DCR) as Per RECIST v1.1 Using ICR and Investigator Assessment

DCR at 6 weeks was defined as the percentage of participants who had the best objective response (BoR) of confirmed CR or PR, or who had stable disease (SD) (without subsequent cancer therapy), for at least 5 weeks after first dose of study treatment. DCR at 12 weeks was defined as the percentage of patients who had the BoR of confirmed CR or PR, or who had SD (without subsequent cancer therapy), for at least 11 weeks after first dose of study treatment. CR was defined as disappearance of all TL and PR was defined as at least a 30% decrease in sum of the dms of TL, taking as reference the baseline sum of dms as long as criteria for PD were not met. SD was defined as neither sufficient shrinkage to qualify for PR nor sufficient increase to qualify for PD (\>=20% increase in sum of dms of TLs and an absolute increase of \>=5 millimeters, taking as reference smallest sum of dms since treatment started including baseline sum of dms). CI was calculated using Clopper-Pearson method.

Time frame:
Tumor scans performed at screening, then q6w +/- 1 week relative to the date of first treatment administration until RECIST v1.1 objective PD, withdrawal of consent, or death by any cause, up to DCO date of 25 Jan 2023 (approximately 24 months)
Reported as:
Number · percentage of participants
Disease Control Rate (DCR) as Per RECIST v1.1 Using ICR and Investigator Assessment
percentage of participantsT-DXd
DCR at 6 weeks by ICR75.5 (66.0 to 83.5)
DCR at 6 weeks by Investigator assessment70.6 (60.7 to 79.2)
DCR at 12 weeks by ICR53.9 (43.8 to 63.8)
DCR at 12 weeks by Investigator assessment55.9 (45.7 to 65.7)
SecondaryPFS as Per RECIST v1.1 Using ICR and Investigator Assessment

PFS was defined as the time from first dose of study treatment until the date of objective disease progression or death (by any cause in the absence of progression) regardless of whether the participant withdrew from assigned therapy or received another anti-cancer therapy prior to progression (i.e. date of PFS event or censoring - date of first dose + 1). PFS was calculated using the Kaplan-Meier technique. CI for median PFS derived based on the Brookmeyer-Crowley method.

Time frame:
Tumor scans performed at screening, then q6w +/- 1 week relative to the date of first treatment administration until RECIST v1.1 objective PD or death by any cause, up to DCO date of 25 Jan 2023 (approximately 24 months)
Reported as:
Median · months
PFS as Per RECIST v1.1 Using ICR and Investigator Assessment
monthsT-DXd
PFS by ICR5.4 (2.7 to 7.1)
PFS by Investigator assessment4.4 (2.8 to 5.6)
SecondaryPercentage of Participants Alive and Progression-Free at 6 and 12 Months as Per RECIST v1.1 Using ICR and Investigator Assessment

Percentage of participants alive and progression-free at 6 and 12 months are reported. It was calculated using the Kaplan-Meier technique. CI for median PFS derived based on the Brookmeyer-Crowley method.

Time frame:
At Months 6 and 12
Reported as:
Number · percentage of participants
Percentage of Participants Alive and Progression-Free at 6 and 12 Months as Per RECIST v1.1 Using ICR and Investigator Assessment
percentage of participantsT-DXd
PFS rate at 6 months by ICR41.4 (30.8 to 51.6)
PFS rate at 6 months by Investigator assessment37.7 (28.1 to 47.2)
PFS rate at 12 months by ICR30.9 (20.6 to 41.8)
PFS rate at 12 months by Investigator assessment26.5 (17.2 to 36.7)
SecondaryConfirmed ORR as Per RECIST v1.1 Using Investigator Assessment

Confirmed ORR was defined as the percentage of participants who had a confirmed CR or PR as determined by investigator per RECIST v1.1. A CR was defined as disappearance of all TLs and PR was defined as \>=30% decrease in the sum of the dms of TL, taking as reference the baseline sum of dms as long as criteria for PD were not met.

Time frame:
Tumor scans performed at screening, then q6w +/- 1 week relative to the date of first treatment administration until RECIST v1.1 objective PD, withdrawal of consent, or death by any cause, up to DCO date of 25 Jan 2023 (approximately 24 months)
Reported as:
Number · percentage of participants
Confirmed ORR as Per RECIST v1.1 Using Investigator Assessment
percentage of participantsT-DXd
Confirmed ORR as Per RECIST v1.1 Using Investigator Assessment32.4 (23.4 to 42.3)
SecondaryOverall Survival (OS)

OS was defined as the time from the date of first dose of study treatment administration until death due to any cause regardless of whether the patient withdrew from therapy or received another anti-cancer therapy (i.e. date of death or censoring - date of first dose + 1). OS was calculated using the Kaplan-Meier technique. CI for median OS derived based on the Brookmeyer-Crowley method.

Time frame:
From the date of first treatment administration up to death, approximately 24 months
Reported as:
Median · months
Overall Survival (OS)
monthsT-DXd
Overall Survival (OS)10.9 (8.3 to 14.9)
SecondaryPercentage of Participants Alive at 6 and 12 Months

Percentage of participants alive at 6 and 12 months are reported. It was calculated using the Kaplan-Meier technique. CI for median PFS derived based on the Brookmeyer-Crowley method.

Time frame:
At Months 6 and 12
Reported as:
Number · percentage of participants
Percentage of Participants Alive at 6 and 12 Months
percentage of participantsT-DXd
Survival rate at 6 months67.6 (57.4 to 75.9)
Survival rate at 12 months46.3 (35.7 to 56.3)
SecondarySerum Concentrations of T-DXd and Total Anti-HER2 Antibody

Serum samples were collected at specified timepoints to determine serum concentrations of T-DXd and total anti-HER2 antibody.

Time frame:
Pre-infusion and 15 minutes post-infusion in Cycles 1, 2 and 4 and 5 hours post-infusion in Cycle 1 (each cycle 21 days)
Reported as:
Mean · microgram/milliliter (mL)
Serum Concentrations of T-DXd and Total Anti-HER2 Antibody
microgram/milliliter (mL)T-DXd
T-DXd: Cycle 1: Pre-infusionNA ± NA
T-DXd: Cycle 1: 15 minutes post-infusion116.5 ± 50.8
T-DXd: Cycle 1: 5 hours post-infusion115.4 ± 30.5
T-DXd: Cycle 2: Pre-infusion11.2 ± 74.1
T-DXd: Cycle 2: 15 minutes post-infusion132.2 ± 101.5
T-DXd: Cycle 4: Pre-infusion7.7 ± 9.1
T-DXd: Cycle 4: 15 minutes post-infusion121.7 ± 40.1
Total anti-HER2 antibody: Cycle 1: Pre-infusionNA ± NA
Total anti-HER2 antibody: Cycle 1: 15 minutes post-infusion123.8 ± 52.8
Total anti-HER2 antibody: Cycle 1: 5 hours post-infusion122.1 ± 42.1
Total anti-HER2 antibody: Cycle 2: Pre-infusion6.2 ± 12.4
Total anti-HER2 antibody: Cycle 2: 15 minutes post-infusion144.4 ± 115.4
Total anti-HER2 antibody: Cycle 4: Pre-infusion9.9 ± 5.7
Total anti-HER2 antibody: Cycle 4: 15 minutes post-infusion122.1 ± 37.3
SecondarySerum Concentrations of Deruxtecan (MAAA-1181a)

Serum samples were collected at specified timepoints to determine serum concentrations of MAAA-1181a.

Time frame:
Pre-infusion and 15 minutes post-infusion in Cycles 1, 2 and 4 and 5 hours post-infusion in Cycle 1 (each cycle 21 days)
Reported as:
Mean · ng/mL
Serum Concentrations of Deruxtecan (MAAA-1181a)
ng/mLT-DXd
MAAA-1181a: Cycle 1: 15 minutes post-infusion4.7 ± 2.9
MAAA-1181a: Cycle 1: 5 hours post-infusion10.5 ± 5.1
MAAA-1181a: Cycle 2: Pre-infusion0.2 ± 0.1
MAAA-1181a: Cycle 2: 15 minutes post-infusion2.2 ± 1.5
MAAA-1181a: Cycle 4: Pre-infusion0.3 ± 0.2
MAAA-1181a: Cycle 4: 15 minutes post-infusion1.5 ± 0.9
SecondaryPercentage of Participants With Anti-Drug Antibodies (ADA) to T-DXd

Blood samples were collected to evaluate the presence of ADAs for T-DXd using validated assays. ADA prevalence was defined as the percentage of participants with positive ADA result at any time, baseline or post-baseline. ADA incidence was defined as the percentage of participants who were evaluable for ADA and were treatment-emergent ADA-positive. Treatment-emergent ADA was defined as either treatment-induced (baseline ADA negative, post-baseline ADA positive) or treatment-boosted ADA. Treatment-boosted ADA was defined as baseline positive ADA titer that was boosted to \>=2 fold during the study period. Persistently positive was defined as \>=2 post-baseline ADA positive measurements with at least 16 weeks (112 days) between the first and last positive measurements, or an ADA positive result at the last available assessment. Transiently positive was defined as having \>=1 post baseline ADA positive measurement and not fulfilling the conditions for persistently positive.

Time frame:
Up to approximately 24 months
Reported as:
Number · percentage of participants
Percentage of Participants With Anti-Drug Antibodies (ADA) to T-DXd
percentage of participantsT-DXd
ADA positive at any visit (ADA prevalence)2.1
ADA incidence0
Treatment-emergent ADA positive0
Treatment-boosted ADA positive0
Persistently positive ADA0
Transiently positive ADA0

Adverse events

Collected over Treatment-emergent adverse events were collected from start of first dose of study treatment up to and including 47 days following the date of last dose of study treatment or before the initiation of first subsequent anti-cancer therapy following discontinuation of study treatment (whichever occurred first), up to DCO date of 25 Jan 2023 (approximately 24 months). Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
T-DXd58/102 (56.9%)36/102 (35.3%)96/102 (94.1%)
Most frequent serious events
Showing 10 of 43
Most frequent serious events
EventT-DXd
PneumonitisRespiratory, thoracic and mediastinal disorders4/102
Bone painMusculoskeletal and connective tissue disorders2/102
Acute kidney injuryRenal and urinary disorders2/102
AnaemiaBlood and lymphatic system disorders2/102
DyspnoeaRespiratory, thoracic and mediastinal disorders2/102
ConstipationGastrointestinal disorders2/102
VomitingGastrointestinal disorders2/102
AstheniaGeneral disorders2/102
CholangitisHepatobiliary disorders2/102
Biliary tract infectionInfections and infestations2/102
Most frequent other events
Showing 10 of 28
Most frequent other events
EventT-DXd
NauseaGastrointestinal disorders49/102
AnaemiaBlood and lymphatic system disorders35/102
FatigueGeneral disorders31/102
DiarrhoeaGastrointestinal disorders28/102
Decreased appetiteMetabolism and nutrition disorders24/102
AstheniaGeneral disorders19/102
Aspartate aminotransferase increasedInvestigations18/102
AlopeciaSkin and subcutaneous tissue disorders18/102
ConstipationGastrointestinal disorders18/102
Neutrophil count decreasedInvestigations15/102

Baseline characteristics

The Full Analysis Set (FAS) consisted of all participants who received at least 1 dose of study treatment.

Age, Continuous
Age, Continuous(years)T-DXd
Mean64.2 ± 10.29
Sex: Female, Male
Sex: Female, Male(Participants)T-DXd
Female62
Male40
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)T-DXd
Hispanic or Latino2
Not Hispanic or Latino91
Unknown or Not Reported9
Race (NIH/OMB)
Race (NIH/OMB)(Participants)T-DXd
American Indian or Alaska Native0
Asian38
Native Hawaiian or Other Pacific Islander0
Black or African American2
White51
More than one race0
Unknown or Not Reported11
08

Study locations

30 sites
  • Research Site
    Santa Rosa, California 95403, United States
  • Research Site
    Muncie, Indiana 47303, United States
  • Research Site
    Boston, Massachusetts 02115, United States
  • Research Site
    Boston, Massachusetts 02215, United States
  • Research Site
    Middletown, New Jersey 07748, United States
  • Research Site
    Commack, New York 11725, United States
  • Research Site
    Harrison, New York 10604, United States
  • Research Site
    New York, New York 10021, United States
  • Research Site
    Houston, Texas 77030, United States
  • Research Site
    Fairfax, Virginia 22031, United States
  • Research Site
    Anderlecht, 1070, Belgium
  • Research Site
    Toronto, CA M5G 2M9, Canada
  • Research Site
    Copenhagen, 2100, Denmark
  • Research Site
    Bordeaux, 33076, France
  • Research Site
    Lyon, 69008, France
  • Research Site
    Villejuif, 94805, France
  • Research Site
    Milan, 20141, Italy
  • Research Site
    Milan, 20162, Italy
  • Research Site
    Naples, 80131, Italy
  • Research Site
    Chūōku, 104-0045, Japan
  • Research Site
    Kashiwa, 277-8577, Japan
  • Research Site
    Suita-shi, 565-0871, Japan
  • Research Site
    Seoul, 03080, South Korea
  • Research Site
    Seoul, 03722, South Korea
  • Research Site
    Seoul, 06351, South Korea
  • Research Site
    Barcelona, 08035, Spain
  • Research Site
    Madrid, 28041, Spain
  • Research Site
    Madrid, 28050, Spain
  • Research Site
    Pamplona, 31008, Spain
  • Research Site
    Seville, 41013, Spain
09

References and documents

Publications

  • Li BT, Meric-Bernstam F, Bardia A, Naito Y, Siena S, Aftimos P, Anderson I, Curigliano G, de Miguel M, Kalra M, Oh DY, Park JO, Postel-Vinay S, Rha SY, Satoh T, Spanggaard I, Michelini F, Smith A, Machado KK, Saura C; DESTINY-PanTumor01 study group. Trastuzumab deruxtecan in patients with solid tumours harbouring specific activating HER2 mutations (DESTINY-PanTumor01): an international, phase 2 study. Lancet Oncol. 2024 Jun;25(6):707-719. doi: 10.1016/S1470-2045(24)00140-2. Epub 2024 May 3. PubMed 38710187 ↗
  • Jhaveri K, Eli LD, Wildiers H, Hurvitz SA, Guerrero-Zotano A, Unni N, Brufsky A, Park H, Waisman J, Yang ES, Spanggaard I, Reid S, Burkard ME, Vinayak S, Prat A, Arnedos M, Bidard FC, Loi S, Crown J, Bhave M, Piha-Paul SA, Suga JM, Chia S, Saura C, Garcia-Saenz JA, Gambardella V, de Miguel MJ, Gal-Yam EN, Rapael A, Stemmer SM, Ma C, Hanker AB, Ye D, Goldman JW, Bose R, Peterson L, Bell JSK, Frazier A, DiPrimeo D, Wong A, Arteaga CL, Solit DB. Neratinib + fulvestrant + trastuzumab for HR-positive, HER2-negative, HER2-mutant metastatic breast cancer: outcomes and biomarker analysis from the SUMMIT trial. Ann Oncol. 2023 Oct;34(10):885-898. doi: 10.1016/j.annonc.2023.08.003. Epub 2023 Aug 18. PubMed 37597578 ↗

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: Yes — Qualified researchers can request access to anonymized individual patient-level data from AstraZeneca group of companies sponsored clinical trials via the request portal. All request will be evaluated as per the AZ disclosure commitment: https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure. Yes, indicates that AZ are accepting requests for IPD, but this does not mean all requests will be shared.

Supporting information: Study protocol, Statistical analysis plan

Time frame: AstraZeneca will meet or exceed data availability as per the commitments made to the EFPIA Pharma Data Sharing Principles. For details of our timelines, please rerefer to our disclosure commitment at https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure.

Access criteria: When a request has been approved AstraZeneca will provide access to the de-identified individual patient-level data in an approved sponsored tool . Signed Data Sharing Agreement (non-negotiable contract for data accessors) must be in place before accessing requested information. Additionally, all users will need to accept the terms and conditions of the SAS MSE to gain access. For additional details, please review the Disclosure Statements at https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure.

Data sharing details ↗ · astrazenecagroup-dt.pharmacm.com

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Dec 2020 to primary completion in Jan 2023, 24 months.

Results were first posted in Feb 2024, 1 year after primary completion.

Of 88 industry-sponsored phase 2 interventional studies under Neoplasm Metastasis, half reached primary completion within 33 months of starting (the median), counting those still running; a quarter within 26 and three quarters within 63. This study's 24 months is below that.

Counting every sponsor, half of 443 studies reached it within 56 months; a quarter within 33 and three quarters within 83.

How these figures are worked out, and which studies are left out of them.

Registered
Oct 26, 2020
First posted
Nov 20, 2020
StartActual
Dec 30, 2020
Primary completionActual
Jan 25, 2023
CompletionEst.
Jul 14, 2026
Results first posted
Feb 15, 2024
Last update
Mar 23, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Mar 23, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT04639219
Lead sponsor
AstraZeneca
Responsible party
Sponsor
First posted
Nov 20, 2020
Start date
Dec 30, 2020
Primary completion
Jan 25, 2023
Completion
Jul 14, 2026 (estimated)
Results posted
Feb 15, 2024
Last update
Mar 23, 2026

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in Mar 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Trastuzumab deruxtecan

Start the discussion